Posts Tagged :

QUIBIM Precision

OCT2019quibim

QUIBIM at the annual Outsourcing in Clinical Trials Europe 2019

We are very happy to share with you QUIBIM´s experience at the last Outsourcing in Clinical Trials Europe 2019 from 14th to 15th of May in Milan (Italy).

Clinical Trials Manager and Chief Strategy Officer, Irene Mayorga and Kabir Mahajan, joined this annual meeting to introduce the services that QUIBIM offers to CRO’s and pharmaceutical companies conducting imaging clinical trials. They had the pleasure of interacting with many novel drug development companies & CRO’s focusing on glioblastoma, pancreatic cancer, other cancers and diffused liver disease and had the chance to show QUIBIM´s experience on this front.

Also, we had the opportunity to discuss QUIBIM´s services as an imaging core lab, not only with the scientific and technical aspects, but also with the design and development of imaging documentation such as the imaging trial charter, the medical imaging validation and imaging acquisition quality control,  statistical analysis and other standard clinical trials management services.

If you did not have the chance to join us in Milan, you can meet Irene Mayorga Ruiz and Kabir Mahajan at the BIO Convention in Philadelphia from June 3- June 6, 2019 where they would be showing the latest developments in the QUIBIM Precision platform for managing clinical trials. You can use the following link to book a demo.

image2

Breast cancer QUIBIM

QUIBIM uses AI to boost
breast cancer research
As the first ESMO Breast Cancer Congress unfolded 2-4 May in Berlin, Germany, QUIBIM CEO highlighted the role played by artificial intelligence (AI) in breast cancer research.

The European Society of Medical Oncology focused on the progress in treatment options and improved outcomes for breast cancer (BC) patients during its first meeting dedicated to the topic (¹).

One of the key messages of the conference was that therapeutic innovations should go hand in hand with a multidisciplinary, fully integrated approach to patient care, a scenario in which AI can increasingly help make a difference, according to QUIBIM CEO & founder Angel Alberich-Bayarri.

Breast cancer_QUIBIM

QUIBIM breast cancer structured report

“AI, and in particular image quantification, can help significantly advance knowledge of this multi-faceted disease, by enabling earlier and better detection,” he said.

From the Pacific to the rest of the world

Recently QUIBIM partnered with the AI Precision Health Institute (AI-PHI) at the University of Hawai‘i Cancer Center in Honolulu, to manage, store and quantitatively analyze medical images and algorithms in breast cancer research.

Using the QUIBIM Precision® image analysis platform, AI-PHI researchers will create large scale imaging repositories with automated extraction of imaging biomarkers to characterize patients’ status. The solution will first be used as the central repository for the mammography studies conducted in the Pacific and will include mammograms from over 5 million women.

The University of Hawai‘i Cancer Center is one of 69 NCI designated cancer centers in the United States and the only one in Hawai‘i and all of the Pacific Islands. It is the only institution that uses AI to analyze medical images to assess health and predict risk of disease in the region.

The project is expected to grow exponentially as its principal investigator Dr. John Shepherd is keen on inviting selected reference centers all across the world to join the network. “It is a very interesting and pioneering work for QUIBIM, and our first big cooperation in the breast cancer setting,” Alberich said.

Seamless integration into clinical workflow

The QUIBIM Precision® image analysis platform enables to incorporate AI algorithms regardless of the institution where it is deployed, to facilitate integration into workflow.

“Researchers can program their own algorithm and code, and add it as a plugin to the platform. This feature, combined with the advanced storage and multi-user annotation capabilities of the platform, allows for a wide adoption within research groups and institutions working with AI. Time for deployment of algorithms in the real world is shortened by 25%, since you have the whole AI pipeline in just one place,” he explained.

The solution, which includes not only quantitative image analysis but also structured reporting capabilities, can be integrated into the radiology workflow and add value to this service. It can for instance be used to integrate AI algorithms to detect cancer without the need of radiologists in a first-read.

Earlier this year the platform received CE Mark certification as class IIa Medical Device, including the imaging biomarker analysis algorithms, the zero footprint DICOM viewer and the platform hosting these components and medical imaging data. The platform is now available for commercial deployment in European hospitals and diagnostic imaging centers.

In addition to the platform, the certification includes 15 algorithms in the five key areas of interest of the company: oncology, neurology, musculoskeletal, liver and lung. 

Also included in the CE Mark certification is the DataMiner, which was designed in collaboration with the team of Prof. Daniel Keim from Konstanz University to provide advanced visual analytics of large databases of patients for population health management and scientific exploitation. The DICOM web viewer that enables the user to visualize the images of a sequence, draw ROIs or apply filters is also included in the certification.

QUIBIM applies machine learning to develop tools for imaging data quantification, to accelerate image reconstruction, segmentation, detection and data mining. Beyond the breast, the company has created AI algorithms to help detect changes produced by brain and prostate cancer, but also other diseases in the hematological scenario such as non-Hodgkin’s Lymphoma.

(¹): https://www.esmo.org/Conferences/ESMO-Breast-Cancer-2019?utm_campaign=PRESS%20-%20Breast&utm_source=hs_email&utm_medium=email&utm_content=72075686&_hsenc=p2ANqtz-9pH5mSHFhwzXnTGp6oSizohrD75uXccBxo1woBVGUFhJl3K5y_p4Ms4Hoa3LcwRJ_KvILSmOWhsrZxTZSWLwumEXOnOw&_hsmi=72075686

QUIBIM team

La biotecnológica Quibim asume la gestión del banco de imágenes médicas del Pacífico e Italia

  • La empresa participada por Angels, la sociedad de inversión de Juan Roig, cierra un convenio para formar a 5.000 radiólogos tras adaptar su plataforma de extracción de biomarcadores Quibim Precision como herramienta educativa

  • La empresa, que abre nueva sede en Valencia, permite ahorrar tiempo y dinero al sector de los ensayos clínicos gracias a su sistema de cuantificar parámetros en radiología y medicina nuclear

València, 18 de abril de 2019.- La biotecnológica valenciana Quibim ha asumido la gestión del biobanco de imágenes médicas del Pacífico, tras cerrar un acuerdo con el centro de investigación del cáncer de la Universidad de Hawaii. La startup, participada por la sociedad de inversión de Juan Roig Angels, acaba de convertirse, además, en proveedor de este mismo servicio para imágenes médicas en Italia, gracias al sistema Quibim Precision, una plataforma de algoritmos de inteligencia artificial y análisis de imágenes radiológicas que fue desarrollado por esta joven empresa (fundada en 2012) con financiación del programa H2020 de la Comisión Europea.

El sistema Quibim Precision permite analizar imágenes médicas en la nube -aunque puede instalarse en versiones locales en hospitales o compañías- a partir de pruebas de rayos X, ecografías, TAC, resonancias magnéticas (RNM) o PET. Gracias a la aplicación de algoritmos de análisis, el software de Quibim posibilita extraer datos cuantitativos, que sirven para que el profesional médico haga el diagnóstico con más información.

Estos parámetros extraídos reciben el nombre de Biomarcadores de Imagen y aportan datos extraídos de imágenes médicas, relacionadas con procesos biológicos normales, enfermedades (por ejemplo tumores) o respuestas terapéuticas. Los modelos computacionales aplicados a las imágenes sirven para medir de manera objetiva los cambios producidos por una lesión o por tratamientos farmacológicos.

La tecnología Quibim se aplica en la práctica clínica, los ensayos clínicos, la formación en radiología y los proyectos de investigación. Con la adaptación de la plataforma al sector de la investigación se puede hacer una evaluación más temprana sobre la respuesta a los tratamientos en ensayos clínicos, con el consiguiente ahorro de tiempo y dinero, aspectos clave en cualquier proyecto de I+D+i.

Quibim ha cerrado un acuerdo con la Escuela Europea de Radiología (European School of Radiology, ESOR) para que su plataforma de apoyo al diagnóstico sirva como herramienta de formación para más de 5.000 radiólogos en todo el mundo. Ello gracias a que la plataforma ha sido adaptada como instrumento educativo. Actualmente, los radiólogos han de recurrir a meras imágenes proyectadas en power point en sus procesos formativos. La joven startup está inmersa en un proceso de expansión internacional. Hoy está ya presente en España, Reino Unido, Italia, Holanda, Dinamarca, Polonia, Portugal, Chile, Uruguay, Argentina, Estados Unidos, Taiwán, Japón e India.

Entre sus objetivos en este 2019, tras conseguir el marcado CE el pasado año, está conseguir la certificación FDA -un prestigioso sello médico para comercializar en Estados Unidos-  para consolidar una fuerte presencia en este país, ampliar la cobertura  a 60 hospitales y centros de diagnóstico y participar en una docena de nuevos ensayos clínicos de ámbito nacional e internacional.

Inaugura sede corporativa en Valencia

Quibim acaba de inaugurar nueva sede corporativa en Valencia, en el Edificio  Europa, uno de los hubs de negocio de la ciudad. La compañía biotecnológica ha crecido en los últimos cinco años hasta convertirse en una de las siete pymes que lidera mundialmente el desarrollo de tecnologías de postprocesado de imágenes médicas basadas en inteligencia artificial. Cuenta también con oficinas en Madrid y Palo Alto (California). En la compañía trabajan ya una veintena de profesionales.

Según Ángel Alberich-Bayarri, CEO y fundador de la compañía, “estas nuevas instalaciones representan un paso más para la compañía. Comenzamos de forma activa en 2014 con una idea dentro del programa Lanzadera y hoy celebramos con la inauguración de nuestra nueva oficina la evolución que ha tenido la empresa a lo largo de estos años, un gran hito para QUIBIM”.

Sobre Angels

Angels es la sociedad de inversión impulsada por el empresario Juan Roig que tiene como objetivo invertir en líderes emprendedores para desarrollar empresas sostenibles. Ofrece un modelo de gestión basado en el Modelo de Calidad Total, su red de contactos, así como toda la infraestructura necesaria para acompañar al emprendedor, comenzando por las oficinas situadas en el entorno del polo emprendedor Marina de Empresas.

Sobre TechTransfer UPV

Tech Transfer UPV es el primer fondo de transferencia de tecnología impulsado dentro del sistema universitario español que apuesta por proyectos de transferencia de tecnología y emprendimiento generados en la Universitat Politècnica de València para acompañarlos en su salida al mercado.

Dispone de un patrimonio de 3,9 millones de euros. El Fondo está participado por 28 empresarios y profesionales valencianos y de Castellón de diferentes sectores que, además de invertir, participan como validadores de los proyectos. Entre ellos, el Instituto Valenciano de Finanzas, Caixa Popular Productos Citrosol, Air Nostrum, Grupo IVI, Multiscan, ACAL, Arca Telecom, S2 Grupo, Miarco, La Unión Alcoyana Seguros, Nero Family, Blast of partners, Tecnopaking, Vik Consultoría o Ca&CCA ingeniería.

QUIBIM TEAM ECR 2019

ECR 2019 sets the trend in Artificial Intelligence

The city of Vienna was at the real core of Medical Imaging and AI at the 25th European Congress of Radiology (ECR). At QUIBIM we always enjoy being at this annual meeting because it is the perfect combination of a science and industry exhibition. In this edition, the congress reached the milestone of 30,000 attendees, and the numbers are expected to go up with each year.

QUIBIM was glad to be participating in both, the scientific and industry sessions. Our oral presentations were mainly addressing current challenges of artificial intelligence (AI) and convolutional neural networks (CNN) in clinical needs like metabolic disorder, prostate cancer and osteoarthritis. Ana Jiménez-Pastor, Rafael López-González and Fabio García-Castro, R&D Engineers at QUIBIM presented our new research in image processing pipelines aiming to perform a virtual dissection of the organs through an automated segmentation combined with features extraction.

Personally,  I was happy to give 3 lectures focused on the future of radiology: 3D Post-processing in 2019, Deep Learning in Medical Imaging and Start-up in Radiology. In the 3D Post-processing lecture I introduced, what I think is the main revolution of AI in our field the concept of Virtual In-Vivo Dissection (VIVID), a name coined by my team and I at QUIBIM, which is a strategy of isolating human body organs in medical images for  characterization through features such as imaging biomarkers. This has several applications, challenges and is difficult to solve by traditional computer vision algorithms like liver or cartilage segmentation in Magnetic Resonance Imaging but it has become a reality thanks to the use of CNN architectures such as U-Net combined with deep supervision. In the Deep Learning in Medical Imaging session, I  focused on using other presentation formats and I was glad to give a TED talk and share the podium with Dr. Wiro Niessen, who spoke about Machine Learning in a Pecha Kucha format. This session was organized by the European School of Radiology (ESOR) and was chaired by Prof. Dr. Valérie Vilgrain, and I must say the atmosphere was excellent and the room was really packed! Finally, in a session chaired by Prof. Dr. Elmar Kotter,  we shared our insights on how to create a start-up company in Radiology from scratch, how to get funding from investors and the main considerations when scaling-up.

QUIBIM was also invited by the ECR to give a presentation within the Artificial Intelligence Exhibition (AIX) sessions, a new space for innovative AI companies. During this session, moderated by Dr Hugh Harvey and Dr Wim Van Hecke, we presented the newest version of the QUIBIM Precision V3.0 platform launched at the last RSNA 2018.

boothecr

Meet us at ECR 2019

We are delighted to share that QUIBIM will attend the 25th European Congress of Radiology 2019 (ECR) from Wednesday, February 27th to Sunday, March 3rd, 2019. This year we have changed our standard location, now you can meet us at the AI Exhibition area (EXPO X1) booth #AI-15.

ECR attendees will have the opportunity to explore our latest version of the platform QUIBIM Precision® V3.0, focused on the Symbiosis of Radiology and Artificial Intelligence to seamlessly integrate imaging biomarkers into radiology workflows. Come and try our AI solutions and imaging biomarkers analysis!

Book a DEMO

Make sure not to miss our scientific contributions:

  • Wednesday, February 27:
    • 3D post-processing in 2019 – Dr. Ángel Alberich Bayarri.   |  Imaging Informatics, Artificial Intelligence and Machine Learning (Room N) – 16:00 – 17:30
    • Deeply supervised networks for the automated liver segmentation and quantification on MECSE-MRI – Ana Jiménez Pastor | EPOS
    • Stress testing a deep learning algorithm for normal/abnormal classification of Chest X-rays on a spectrum-biased abnormal – Rafael López Gónzalez  |  EPOS
      weighted dataset.
  • Thursday, February 28:
    • Functional imaging of the liver Chairperson’s introduction – Dr. Luis Martí Bonmatí. |  Abdominal Viscera, Contrast Media (Room M 5) – 10:30 – 12:00
    • AI PITCH – Dr. Ángel Alberich Bayarri.  |  Artificial Intelligence Exhibition (AIX) Theatre ( AIX Theatre) – 11:40
    • What to think about when writing a paper – Dr. Luis Martí Bonmatí. |  Education, General Radiology, Professional Issues (Room: C&T 3) – 14:00 – 15:00
    • Deep learning (DL) in medical imaging – Dr. Ángel Alberich Bayarri.   |  Education, General Radiology, Artificial Intelligence and Machine Learning (Room: M3) – 14:00 – 15:30
    • Quantification and evaluation of pre-post exercise femoral cartilage thickness and T2 changes in ultramarathon athletes – Fabio García Castro  |  Musculoskeletal, Imaging Methods (Room: O) – 14:00 – 15:30
    • How to manage critical reviews – Dr. Luis Martí Bonmatí. |  Education, General Radiology, Professional Issues (Room C&T 3) – 15:00 – 16:00
  • Friday, March 1:
    • ECR Academies: Radiology Leaders’ Bootcamp: Dream team Chairperson’s introduction –Dr. Luis Martí Bonmatí. |  Management/Leadership (Room M 2) – 10:30 – 12:00
    • Start-up in radiology – Dr. Ángel Alberich Bayarri.   |  Management/Leadership (Room M2) –  14:00 – 15:30
  • Saturday, March 2:
    • Automated Prostate multiregional segmentation in Magnetic Resonance using deeply supervised Convolutional Neural Networks – Rafael López González  |  Artificial Intelligence and Machine Learning, Oncologic Imaging, Imaging Informatics, Genitourinary, Physics in Medical Imaging (Room G) – 16:00 – 17:30
  • Sunday, March 3:
    • Automatic visceral fat characterization on CT scans through Deep Learning and CNN for the assessment of metabolic syndrome –  Ana Jiménez Pastor | Artificial Intelligence and Machine Learning, Abdominal Viscera, GI Tract, Oncologic Imaging, Imaging Informatics (Room D) – 14:00 – 15:30
    • Liver Case-Based Diagnosis Training – Dr. Luis Martí Bonmatí. |  Education, General Radiology, General Radiography (Radiographers) (Room E1) – 13:00 – 15:30

Join us at ECR 2019!

 For more information, get in touch with us at contact@quibim.com

FEDER+Ivace+Declaracion-CS

QUIBIM recibe la ayuda del IVACE – Certificación I+D+i 2018

QUIBIM ha obtenido financiación del Institut Valencià de Competitivitat Empresarial (IVACE) dentro del programa Certificación I+D+i 2018. Una ayuda financiera de la Unión Europea (Expediente: IMACPA/2018/205) para la realización del proyecto “DESARROLLO DE NUEVOS ALGORITMOS DE INTELIGENCIA ARTIFICIAL APLICADOS AL ANÁLISIS AUTOMATIZADO DE BIOMARCADORES”. 

El objetivo del proyecto es el desarrollo de nuevos algoritmos para la segmentación automática de distintas áreas anatómicas del cuerpo humano (espina dorsal, hígado, pulmón, corazón, etc.). Estos algoritmos, basados en nuevas técnicas de Inteligencia Artificial, están específicamente diseñados y entrenados para discernir las regiones a analizar, segmentar órganos específicos y realizar mediciones automatizadas de biomarcadores de imagen.

QUIBIM_chest_xray_classifier_logo3

New Chest X-Ray Classification Tool

Despite the technological evolution of imaging modalities like CT, US and MRI, conventional X-ray remains the most performed examination in radiology departments, and remains a fundamental tool for anatomical analysis in the detection and diagnosis of respiratory diseases and bone tissue alterations. However, radiology departments have limitations in reporting the X-Rays due to the limited resources available (link).

QUIBIM has developed a Chest X-Ray Classification Tool that offers a solution to this problem which can help radiology departments become even more efficient. This classifier developed in collaboration with Hospital Universitario y Politécnico La Fe, estimates the probability of chest X-Rays of having a pathology using Artificial Intelligence.

How does it work?

This tool makes use of fourteen Convolutional Neural Networks trained with a database of more than 100,000 images (NIH ChestXray14 dataset) to estimate the probability of presence of the following pathologies in chest X-Rays: atelectasis, cardiomegaly, effusion, infiltration, mass, nodule, pneumonia, pneumothorax, consolidation, edema, emphysema, fibrosis, pleural thickening and hernia. Afterwards, the probabilities are used by a Fully Connected Neural Network to get the final probability of the X-Ray of being abnormal.

XRAY chest

Because of this AI methodology the classifier understands the visual patterns that are most indicative of the different pathologies using the knowledge extracted from the large dataset of radiographs used to train the networks. QUIBIM’s Chest X-Ray Classification Tool is able to learn further using new images, which means that this system is continually improving and evolving with time.

 What information does it provide?

Once all the quantifications are performed this tool provides an intuitive Structured Report with the patient’s information, the abnormal probability of the radiographs analyzed and the representation of the findings. In addition, if the image is classified as abnormal, the report shows the three pathologies that are more likely to be found and a heatmap that highlights the most abnormal regions. This report is designed to be very user friendly, to assist the user in understanding the tool’s findings at a glance in order to make its usage highly efficient.

Why is this new tool so useful?

Using this technology it is possible to prioritize unreported, potentially pathological radiographs which allows radiologists to focus their efforts on studies that are more likely to have pathologies and thereby become more efficient. This tool essentially ensures that pathological findings, which could have been unreported due to the heavy workload of radiology departments, are correctly reported.

QUIBIM’s goal is to provide the radiology departments with an optimal solution for automatic reading of X-Rays without interfering in the  workflow of the department.

QUIBIM’S Chest X-Ray Analysis Tool is already available at QUIBIM Precision® Depending on the needs of the department, this tool is accessible through the cloud with just a few clicks  or  it can be fully integrated in the radiology department’s workflow as a local solution for  seamless interpretation of  chest X-Rays.

boton try quibim

QUIBIM se posiciona en el mercado americano analizando hábitats tumorales y enfermedades difusas hepáticas

Ha cerrado acuerdos con la compañía EnvoyAI y ha abierto oficina en Silicon Valley

QUIBIM sigue creciendo en el desarrollo de algoritmos de análisis de imágenes médicas basados en modelos biológicos y en inteligencia artificial. La compañía, que cerró el año 2017 con un crecimiento del 500% en sus métricas de negocio (número de análisis y facturación), ha avanzado con la expansión al mercado americano de sus algoritmos para cáncer y enfermedades difusas hepáticas. Entre los hitos más relevantes, además de la reciente apertura de oficina en Palo Alto (Silicon Valley, California), QUIBIM ha establecido una alianza con la empresa EnvoyAI, dedicada a la integración y distribución de algoritmos de inteligencia artificial para imágenes médicas. EnvoyAI fue adquirida el año 2016 por TeraRecon, empresa con un software de visualización radiológica que se encuentra actualmente instalado en el 85% de los hospitales de Estados Unidos.

Estos algoritmos de QUIBIM para el mercado americano, ahora mismo en proceso de certificación por la Food and Drug Administration (FDA), caracterizan tanto las diferentes subregiones o habitats internos de un tumor como analizan por biopsia virtual hepática las enfermedades difusas tipo esteatosis, sobrecarga de hierro, inflamación y fibrosis.

En el ámbito de la oncología, QUIBIM proporciona una metodología que extrae datos de textura, celularidad y proliferación vascular en los tumores, siendo aplicable en lesiones cerebrales, de mama, próstata, hígado y recto, entre los principales tumores sólidos. Esta metodología puede aplicarse a las imágenes de Resonancia Magnética y Tomografía Computarizada, proporcionando una información pronóstica sobre la evolución de los pacientes y su respuesta a los diferentes tratamientos.

En el ámbito de las enfermedades difusas hepáticas, QUIBIM proporciona un algoritmo para realizar una biopsia virtual hepática, sin dañar al paciente, a partir de las imágenes de Resonancia Magnética y extrayendo la proporción de grasa, concentración de hierro y proporciones de inflamación y fibrosis hepática. Este análisis es de especial relevancia para el estudio y seguimiento de la esteatohepatitis y la hemocromatosis, y en la evaluación de la historia natural y su modificación por el tratamiento en las hepatopatías crónicas y la cirrosis. Actualmente esta información se obtiene a partir de biopsias convencionales, lo que implica un riesgo para el paciente y un sesgo inherente al procedimiento dado que sólo se obtiene información del lugar de la punción, mientras que el algoritmo de QUIBIM permite obtener información de todo el hígado de manera segura.

En palabras de su CEO, el Dr. Ángel Alberich-Bayarri, resumiendo estos hitos “estamos en una fase muy intensa de la compañía y con un crecimiento significativo, y gracias al esfuerzo del equipo hemos podido acelerar varios hitos que teníamos previstos en fases más tardías, como por ejemplo la alianza con EnvoyAI, la solicitud a FDA y la apertura de oficina en EEUU. Los algoritmos que hemos seleccionado para este mercado aportan un valor diferencial que ya hemos podido verificar, recibiendo solicitudes desde algunos hospitales antes de iniciar acciones comerciales.”

QUIBIM es una empresa biotecnológica nacida en Valencia y está especializada en la extracción de información cuantitativa de las imágenes médicas radiológicas y de medicina nuclear, mediante técnicas originales y avanzadas de procesamiento computacional. Estos parámetros extraídos reciben el nombre de Biomarcadores de Imagen y aportan rasgos extraídos de las imágenes médicas, relacionadas con procesos biológicos normales, enfermedades o respuestas terapéuticas.

Además, el equipo ha desarrollado la plataforma QUIBIM Precision® de análisis de imágenes médicas en la nube, que puede instalarse en versiones privadas para hospitales y para compañías farmacéuticas que desarrollen ensayos clínicos. A partir de imágenes de rayos X, Ecografía, TAC, Resonancia Magnética o PET, QUIBIM es capaz de aplicar algoritmos avanzados de análisis con metodologías basadas en procesamiento por GPU (unidades de procesamiento gráfico), Machine Learning o Big Data. El software de QUIBIM permite aportar una mayor información en los diagnósticos y poder evaluar de forma temprana la respuesta a los tratamientos farmacológicos. La compañía fue seleccionada en 2017 para el programa SME Instrument Fase II de la Comisión Europea.

QUIBIM_MIUC

MIUC
the new toolkit of QUIBIM Precision® platform to beat traditional workstations

Quibim has implemented a new toolkit named MIUC (Medical Imaging Universal Connector) to close the gap between hospital IT systems and the Cloud. Whereas the Cloud satisfies the processing requirements, Quibim Precision® handle the functionalities related to communications and management of DICOM objects among the hospitals and radiological centers.

Quibim Precision® allows users in hospitals and radiology departments to have a seamless integration of imaging biomarkers analysis within the radiological workflow, due to the MIUC capabilities combined by the Quibim Precision® Cloud computing environment and the interoperability features implemented in our system. Both image upload and data retrieval are fully automated and users only need to access the PACS when they are notified that a new biomarker report is available.

MIUC is placed inside the hospitals and clinics and it is responsible to establish all the required communications between the PACS and Quibim Precision®. During the analysis of imaging biomarkers, the study is anonymized, sent to the Cloud and analyzed. The final result is a one-page report which is sent back to the MIUC or can be directly visualized in the Quibim Precision® web interface. Furthermore, in clinical environments, the report is converted into DICOM objects and stored in the PACS as a new series within the original study. To identify the original study, the MIUC implements backward traceability in the client side to reidentify the anonymized studies.

Our platform is intended to be used by radiologists, either from a clinical environment, thanks to the MIUC, or as a final user using the web interface. In the clinical environment scenario, radiologists using Quibim Precision® do not have to worry about where the study or the report is. Instead, these issues are transparent to the user, who do not have to perform any action to launch a biomarker process, given that the MIUC rule engine does such work for them. The user will be notified by email when a new biomarker report is ready (and available in both the PACS and the Quibim Precision® web interface).

Nowadays, our Quibim Precision® platform is compliant with the DICOM standard at both communication level and data management and formatting level. Specifically, our platform receives imaging studies from hospitals, radiological centers or pharma companies. Then, the system analyzes the study and obtains quantitative measures, which are stored in a quantitative database and structured in a one-page report on a per-patient basis. Finally, this report is returned back as a result.  Quibim Precision® allows annotating biomarker reports using terms from RadLex and MeSH, enhancing the interoperability of its biomarker reports with other health information systems. In fact, the imaging platform is seamlessly integrated with the hospital PACS, being able to query and retrieve medical studies, processing them and storing the resulting biomarker reports as DICOM objects in the hospital PACS. On the other hand, the processing stage is performed on the Cloud, taking advantage of its benefits: high-performance computing and real-time hardware scalability on demand.

But, what has changed?

In previous updates of our platform, we improved the performance, capabilities and user settings view. With this new suite software QUIBIM Precision®- MIUC does query/retrieve the PACS, anonymizes the PACS responses and forwards them to Quibim Precision® in the Cloud. Furthermore, the MIUC leads our solution to a higher level of automation, given that it monitors the PACS querying for incoming studies. Once a new study reaches the PACS, the MIUC analyzes its header and determines whether a new biomarker analysis must be launched or not, depending on some DICOM elements in the study like imaging modalities, study description, series description or body part among others. For each biomarker analysis available in Quibim Precision®, there is a predefined set of rules that establishes which studies are susceptible to be processed by each analysis method. An incoming study matches a given analysis method whenever it fulfils the predefined set of rules for such analysis method. When this happens, the MIUC automatically sends the study to the Quibim Precision® Cloud processing platform, where it will be processed by the matching biomarker analysis pipeline. Once processed, a biomarker report is generated with the results and sent back to the MIUC. Finally, the MIUC stores the report in the PACS as a DICOM object, making the report available for the specialist who requested it. This way, the Cloud platform remains centralized and, at the same time, fully integrated with the hospital IT systems.

With the arrival of MIUC toolkit the need for conventional workstations with expensive licenses in radiology departments completely disappears. As in other business areas that are evolving from product to service, the Quibim image analysis technology was designed to be offered as the service that puts disruptive image analysis solutions at your fingertips.

025-FEDER2-declaracion14-20

El proyecto QUIBIM recibe el apoyo del FONDO EUROPEO DE DESARROLLO FEDER

QUIBIM es un proyecto empresarial de alto impacto social y sanitario, que extrae información cuantitativa de las imágenes médicas radiológicas, mediante técnicas innovadoras y avanzadas de procesado computacional, con el objetivo de mejorar los procesos de diagnóstico de enfermedades con alta incidencia y evaluar adecuadamente los cambios que producen los tratamientos farmacológicos en el organismo.

Durante 2016 el proyecto de internacionalización QUIBIM ha recibido la ayuda IVACE (ITAPIN IT16 PLANES DE INTERNACIONALIZACIÓN PYME CV 2016) con el apoyo del Fondo Europeo de Desarrollo Regional (FEDER) con el objetivo de presentar nuestros servicios de diagnóstico y análisis avanzado de imagen médica y dar a conocer nuestra plataforma de análisis QUIBIM Precision® para el análisis de Biomarcadores de Imagen.

quibim map